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THE STATISTICAL PERFORMANCE OF
MATCHING-ADJUSTED INDIRECT COMPARISONS
By David Cheng∗ Rajeev Ayyagari† and James Signorovitch†
VA Boston Healthcare System∗ and Analysis Group†
Indirect comparisons of treatment-specific outcomes across sep-
arate studies often inform decision-making in the absence of head-
to-head randomized comparisons. Differences in baseline character-
istics between study populations may introduce confounding bias in
such comparisons. Matching-adjusted indirect comparison (MAIC)
(Signorovitch et al., 2010) has been used to adjust for differences in
observed baseline covariates when the individual patient-level data
(IPD) are available for only one study and aggregate data (AGD)
are available for the other study. The approach weights outcomes
from the IPD using estimates of trial selection odds that balance
baseline covariates between the IPD and AGD. With the increasing
use of MAIC, there is a need for formal assessments of its statisti-
cal properties. In this paper we formulate identification assumptions
for causal estimands that justify MAIC estimators. We then examine
large sample properties and evaluate strategies for estimating stan-
dard errors without the full IPD from both studies. The finite-sample
bias of MAIC and the performance of confidence intervals based on
different standard error estimators are evaluated through simulations.
The method is illustrated through an example comparing placebo arm
and natural history outcomes in Duchenne muscular dystrophy.
1. Introduction. Indirect comparisons refer to comparisons of treatment-
specific outcomes across different studies, as opposed to direct comparisons
of treatments-specific outcomes within a single study. This frequently arises
in clinical, economic, and regulatory evaluations of new treatments (Altman
et al., 2005; Sutton et al., 2008; Wells et al., 2009; Jansen et al., 2011).
Even when a new treatment has been compared with a standard-of-care in
a randomized trial, for example, it is often important for decision-makers to
contextualize expected outcomes with other treatments and external data
sources. The need for indirect comparisons is also especially acute in set-
tings where direct randomized comparisons are unethical or infeasible, such
as in late-stage oncology trials (Adjei, Christian and Ivy, 2009), rare disease
trials, and evaluations of long-term outcomes in open-label extension trials.
Indirect comparisons also inform the design of trials by providing reason-
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2able prior estimates of effect sizes for power calculations and non-inferiority
margins (Snapinn and Jiang, 2011).
Since indirect comparisons involve comparisons between studies for which
assignment was not randomized, the resulting treatment effect estimates
may be confounded by differences in baseline characteristics between stud-
ies. Such differences may exist even though treatment groups within each
study have been randomized. In practice, a host of differences in the design
of each study can bias indirect comparisons. It is essential to consider, ideally
with clinical input, definitions of the the outcome, patient selection, back-
ground care, along with other issues (Pocock, 1976; FDA, 2001; Phillippo
et al., 2016). A non-exhaustive list of considerations is provided in Table 1.
Although a wide range of issues may introduce bias, there are many cases in
which separate studies are found, after careful evaluation, to be sufficiently
similar for an indirect comparison. Registrational trials conducted for differ-
ent treatments within the same indication during similar time periods, for
instance, often share a high degree of similarity. In this paper we assume that
trials are sufficiently similar in design such that attention can be focused on
addressing bias that stems from differences in baseline characteristics.
Table 1
Study design features that may vary across studies and bias indirect comparisons.
Differences in observed baseline characteristics, the final category, are addressed by the
adjustment methods described in this paper.
Aspect of study design
Outcome assessment
Clinical, imaging, or laboratory methods used to process and measure outcomes
Outcome definitions, including timing of assessments
Event ascertainment or adjudication procedures
Patient selection
Inclusion and exclusion criteria
Recruitment process (e.g. motivation, consent process, distance of site to patient)
Disease diagnostic criteria
Background treatments and care settings
Time period and geography, and associated standards of care
Range of treatment options available
Concomitant medications
Baseline patient characteristics
Demographics
Comorbidities
Treatment history
Severity and duration of medical condition
Biomarkers
When individual patient-level data (IPD) are available for both studies,
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the pooled data can essentially be regarded as observational data with a
non-randomized treatment assignment. In this case methods for estimating
treatment effects with non-randomized treatment based on outcome regres-
sion and propensity score approaches are well-established (Lunceford and
Davidian, 2004; Kang and Schafer, 2007). Conducting indirect comparisons
with full IPD can also be viewed as generalizing estimates from one study to
a different target study population (Stuart et al., 2011; Hartman et al., 2015;
Nie et al., 2013; Zhang et al., 2015), which has a long history of application
in regulatory settings in the form of studies with historical controls (FDA,
2001; EMA CHMP, 2006). In practice, many indirect comparisons are con-
ducted in settings where the full IPD are not available for both study popu-
lations. When only aggregate data (AGD) consisting of summary statistics
(e.g. means and standard errors from publications) for outcomes and base-
line covariates are available, Bucher et al. (1997) introduced a widely used
method to compare treatment effects on an appropriate scale of contrast
(e.g. log odds-ratio, risk difference, etc.) relative to a common comparator
group. But, as we discuss in Section 3, this method requires a common com-
parator arm between studies and does not eliminate the risk of bias. If AGD
from a large number of studies are available, mixed treatment comparisons
generalize methods from meta-analysis and Bucher et al. (1997) to allow for
comparisons of treatments within a network of randomized trials that are
linked by common comparators (Lu and Ades, 2004; Nixon, Bansback and
Brennan, 2007). These approaches rely on “consistency” or “exchangeabil-
ity” assumptions, requiring treatment effects to be constant across trials on
a specified scale of contrast. These assumptions are typically violated when
study populations differ in baseline characteristics, particularly those that
modify treatment effects on the chosen contrast scale.
When IPD are available for only one study and AGD are available for
the other, two general approaches have been used. The simulated treat-
ment comparison (STC) method estimates an adjusted mean outcome under
the IPD treatment by fitting an outcome regression model to the IPD and
plugging-in baseline covariates from the AGD (Caro and Ishak, 2010; Ishak,
Proskorovsky and Benedict, 2015). Indirect comparisons can be obtained by
contrasting this prediction with observed mean outcomes in the AGD. If a
non-linear regression model is used, such as a logit link in a logistic regression
model or a log link in a proportional hazards model, this method incurs bias
because expectations do not commute with non-linear functions. Address-
ing this requires parametric assumptions about the full joint distribution
of covariates from the AGD. STC could also be biased when the postu-
lated outcome regression model is mis-specified. An additional method is
4matching-adjusted indirect comparison (MAIC) (Signorovitch et al., 2010),
which estimates mean outcomes for the IPD in the population represented
by the AGD by estimating trial selection odds through a method of moments
approach and re-weighting the IPD. This avoids issues that arise from regres-
sion modeling, though it still generally assumes correctly specified models
for the trial selection odds. MAIC is similar in spirit to a number of other re-
weighting methods that seek to balance covariates between treatment groups
to estimate causal effects (Zubizarreta, 2015; Li, Morgan and Zaslavsky,
2017) and identical to the covariate balancing propensity score used to es-
timate average treatment effects on the treated (Imai and Ratkovic, 2014)
and entropy-balancing (Hainmueller, 2012; Zhao and Percival, 2017) when
a logistic regression model is assumed for the trial assignment model (see
Section 2.2). However, these other methods are largely motivated by con-
cerns about the balancing performance of propensity scores estimated from
parametric models and focus on estimation and inference in other settings
where IPD are fully observed.
Although MAIC has been widely applied in health technology assessments
and health economic and outcome research studies (Signorovitch et al., 2012,
2013; Phillippo et al., 2016; Swallow et al., 2016), few formal evaluations of
its underlying assumptions and statistical properties exist. We aim to partly
address this gap. Specifically, we formalize the problem in the framework of
counterfactual outcomes and formulate identification assumptions for causal
estimands in the setting where IPD is available for only one study in Sec-
tions 2.1 and 2.2. We then study the large sample properties of the MAIC
estimator in Section 2.3 and discuss strategies to estimate the standard error
in the absence of IPD from the AGD trial in Section 2.4. An investigation
of the finite sample performance of the MAIC estimator and standard error
estimators is reported in Section 3. We illustrate the method through an ap-
plication to Duchenne muscular dystrophy in Section 4 and conclude with
some further discussion in Section 5. Proofs are deferred to the Appendix.
2. Method.
2.1. Problem Setup and Notation. For each individual i in either the IPD
or AGD study, let Yi denote a continuous or binary outcome and Xi a p-
dimensional vector of baseline covariates belonging to covariate space X . Let
Zi ∈ {0, 1, 2} denote treatment assignment to either a common comparator
(Zi = 0) or a treatment studied only in the IPD or AGD trial (Zi = 1 or
Zi = 2, respectively), which is randomized within each trial. Let Ti ∈ {1, 2}
denote trial assignment to the IPD trial (Ti = 1) or AGD trial (Ti = 2).
A common comparator is assumed to be available here to facilitate some
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parts of the subsequent exposition, but it is not strictly needed for MAIC.
In cases with single arm studies, the common comparator data is omitted
and Zi = Ti. The IPD, in general, thus consists of independent and identi-
cally distributed (iid) observations DIPD = {(Yi, Zi,Xi) : Ti = 1}. The AGD
consists of data summaries DAGD =
{
Y¯2z, X¯2z, S
2
Y,2z,S
2
X,2z, N2z : z = 0, 2
}
,
where Ntz =
∑
Ti=t I(Zi = z), X¯tz =
∑
Ti=tXiI(Zi = z)/Ntz, and Y¯tz =∑
Ti=t YiI(Zi = z)/Ntz. Among arm z of trial t, the sample variance of the
outcome is S2Y,tz =
∑
Ti=t(Yi − Y¯tz)2I(Zi = z)/(Ntz − 1) and of all covari-
ates is S2X,tz =
∑
Ti=t(Xi − X¯tz)2I(Zi = z)/(Ntz − 1), with  denoting
element-wise exponentiation. The sample covariance matrix for X is not
fully available since the covariance between covariates is typically not re-
ported in publications. Let the total size between trials be N =
∑
t,z Ntz.
The goal of an indirect comparison is to conduct a “fair” comparison
of the mean outcomes under treatment 1 to treatment 2. Let Yi(z) denote
the counterfactual outcome had patient i been treatment with treatment
z. Since IPD is available for only treatment 1, it would only be possible to
adjust the mean outcome under treatment 1 to population of the AGD trial.
The target parameter is thus:
(1) ∆ = E {Y (1)|T = 2} − E {Y (2)|T = 2} .
This parameter represents the average treatment effect on the treated
(ATT) among those assigned to treatment 2. When a different scale for the
treatment effect contrast is of interest, we can consider a generalization:
∆g = g (E {Y (1)|T = 2})− g (E {Y (2)|T = 2}) ,
where g(·) is a given link function. For example, when Y is binary, taking
g(u) = log{u/(1−u)} specifies that ∆g is on the log odds-ratio scale (LOR).
Regardless of the scale of contrast, the main challenge will be to identify and
estimate E {Y (1)|T = 2}. We will focus on ∆ as the target parameter for
conciseness and note that a transformation can be applied to obtain ∆g.
2.2. Identification. As ∆ is defined in terms of unobserved counterfactual
outcomes, we consider the following assumptions required for identification.
Assumption 2.1 Random treatment within trial: Z ⊥⊥ {X, Y (1), Y (0)}|T =
1 and Z ⊥⊥ {X, Y (2), Y (0)}|T = 2.
Assumption 2.2 Consistency: Y = Y (Z) with probability 1.
Assumption 2.3 Positivity of trial assignment: P (T = 1|X = x) ≥ T |X
for all x ∈ X , for some T |X > 0.
6Assumption 2.4 Ignorability of trial assignment for the outcome under
treatment 1: T ⊥⊥ Y (1)|X.
The first assumption refers to the independence of treatment assignment
with covariates and counterfactual outcomes within each trial due to ran-
domization. This assumption would be omitted in the case of single-arm
studies. The consistency assumption states that the observed outcome coin-
cides with the counterfactual outcome under the treatment received, which
excludes settings with interference and different versions of a treatment. The
positivity assumption indicates patients are not assigned to the AGD trial
using a deterministic or nearly deterministic rule in X. This is a non-trivial
assumption that could be violated, for instance, when inclusion/exclusion
criteria between trials are such that the AGD trial includes patients who
are excluded from the IPD trial. In such cases, the underlying trial popu-
lations are not similar enough to conduct an indirect comparison with any
method, without extrapolating beyond the population of the available IPD.
We offer some more discussion on the effects of violating this assumption
in practice in Section 5. The trial assignment ignorability assumption states
that we observe sufficient covariates X such that trial assignment is un-
related to the counterfactual outcome under treatment 1 within strata of
X. This is plausible when the patient populations between the two trials
are similar enough such that conditioning on the observed covariates X is
enough to control for the differences between study populations that could
lead to confounding bias.
Based on these assumptions, the second term of ∆ can be identified as
E {Y (2)|T = 2} = E(Y |Z = 2, T = 2) using Assumptions 2.1 and 2.2. The
first term of ∆ can be identified as:
(2)
E {Y (1)|T = 2} = E [E {Y (1)|X, T = 2} |T = 2]
= E [E {Y |X, Z = 1, T = 1} |T = 2]
= E
{
P (T = 1)
P (T = 2)
P (T = 2|X)
P (T = 1|X)E(Y |T = 1,X, Z = 1)|T = 1
}
= E
{
I(Z = 1)
P (Z = 1|T = 1)
I(T = 1)
P (T = 2)
ω(X)Y
}
= E {I(Z = 1, T = 1)ω(X)Y } /E {I(Z = 1, T = 1)ω(X)} ,
where ω(X) = P (T = 2|X)/P (T = 1|X) denotes the odds of trial assign-
ment given X. We used Assumptions 2.1, 2.2, 2.4 in the second equality, 2.3
in the third and fourth equalities, and 2.1 in the fourth and final equalities.
This suggests that ∆ can be identified if ω(X) can be identified. Even if
ω(X) could not be identified exactly, the last equality shows it would be
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sufficient if ω(X) could be identified up to a constant due to the ratio of
terms involving ω(X).
Before proceeding, we first discuss an alternative to Assumption 2.4 that
leverages the common comparator arm when data on it is available.
Assumption 2.5 Ignorability of trial assignment for the counterfactual dif-
ference: T ⊥⊥ {Y (1)− Y (0)} |X.
To make use of this assumption, the target parameter can be written ∆ =
E {Y (1)− Y (0)|T = 2}−E {Y (2)− Y (0)|T = 2}, where E {Y (2)− Y (0)|T = 2}
is straightforward to identify due to randomization of treatment within trial.
The first term can be identified by:
(3)
E {Y (1)− Y (0)|T = 2} = E [E {Y (1)− Y (0)|X, T = 2} |T = 2]
= E [E {Y (1)− Y (0)|X, T = 1} |T = 2]
= E [E {Y |X, Z = 1, T = 1} − E {Y |X, Z = 0, T = 1} |T = 2]
= E
{
I(Z = 1)
P (Z = 1|T = 1)
I(T = 1)
P (T = 2)
P (T = 2|X)
P (T = 1|X)Y
}
− E
{
I(Z = 0)
P (Z = 0|T = 1)
I(T = 1)
P (T = 2)
P (T = 2|X)
P (T = 1|X)Y
}
where we use Assumption 2.5 in the second equality, 2.1 and 2.2 in the
second equality. The final steps proceeds as in (2), which uses Assumptions
2.3 and 2.1. This alternative assumption could be easier to justify in some
cases. For example, suppose the outcome model can be specified by:
E(Y |Z,X) = β0 + β1I(Z 6= 0) + βT2X+ βT3 I(Z 6= 0)XM + β4I(Z = 2),
where XM ⊆ X is a subset of the prognostic covariates that modify the
treatment effect of the active treatments and the components of β3 are not
exactly the negative of the components of β2 corresponding to the same
covariate in XM . In such cases it suffices to adjust only for the treatment
effect modifiers XM rather than the full set of X that may differ in dis-
tribution between trials (Phillippo et al., 2016). This approach can also
be used to identify ∆g for a non-linear g(·) by writing E {Y (1)|T = 2} =
E {Y (1)− Y (0)|T = 2} + E {Y (0)|T = 2}. The second term can be easily
identified from randomization within trial. This approach offers an alterna-
tive identification strategy but still relies on strong assumptions about the
form of the conditional mean of Y and assumes covariates are known not to
be effect modifiers on the additive scale. Despite its appeal, Assumption 2.5
is not necessarily weaker than 2.4 and should be evaluated based on clinical
input to the extent possible in practice.
8It now remains for us to identify ω(X) from the observed data. Had IPD
been available for both trials, then this would be straightforward. In the
absence of the full IPD, under Assumption 2.3, ω(X) is a solution in h(X)
to the integral equation:
(4) E
{
h(X)I(T = 1)
−→
X
}
− µ∗−→
X2
P (T = 2) = 0,
where
−→
X = (1,XT)T and µ∗−→
X2
= E(
−→
X|T = 2). If h∗(X) is a solution to this
equation and the solution is unique, then it must be that h∗(X) = ω(X).
In general, without any restrictions on h(X), there may not be a unique
solution. However, h(X) can be reasonably parameterized such that there
exists a unique solution. For example, suppose the trial assignment follows
a logistic regression model:
(5) logitP (T = 2|X) = αT−→X,
for some α = (α0,α
T
1 )
T. Then under this model ω(X) = exp(α∗T
−→
X), where
α∗ is the true value of α. Restricting h(X) = ω(X;α) = exp(αT
−→
X), (4) ad-
mits a unique solution becauseQ(α) = E {ω(X;α)I(T = 1)}−αTµ∗−→
X2
P (T =
2) is strictly convex in α (Signorovitch et al., 2010).
Other moment conditions can also be used. Since ω(X) needs only to be
identified up to a constant, an alternative condition is:
(6) E
{
h(X− µ∗X2)I(T = 1)(X− µ∗X2)
}
= 0,
where µ∗X2 = E(X|T = 2). Under model (5), α1 can be identified by simi-
lar arguments by restricting h(X−µX2) = ω(X−µX2 ;α1) = exp{αT1 (X−
µX2)}. This approach identifies ω(X) up to a scalar constant and avoids
estimation of an additional intercept parameter that is not needed for esti-
mating ∆. Another potentially useful condition is:
(7) E {h(X)I(T = 1)t(X)} − E {t(X)|T = 2}P (T = 2) = 0,
where we take t(X) = (1, X1, . . . , Xp, X
2
1 , . . . , X
2
p )
T to be elements of X
and their squares. In contrast to conditions (4) and (6), using this condition
in practice would require the availability of the sample variances of the
covariates in the AGD to estimate E{t(X)|T = 2}. If we again restrict
h(X) = ω(X;α†) = exp{α†Tt(X)}, where α† = (αT,αT2 )T, then ω(X) is
again identified under the more general trial assignment model:
logitP (T = 2|X) = α†Tt(X).
STATISTICAL PERFORMANCE OF MAIC 9
The model from (5) can be viewed as a submodel of this model that restricts
α2 = 0. When (5) is correct, fitting this larger model comes at the cost of
finite-sample efficiency loss. However, if this expanded model is correct, then
using (4) for estimation would yield biased estimates of ω(X) and ∆. Bal-
ancing the first and second moments with this expanded model thus involves
trade-off between robustness and efficiency. We next discuss estimation of
ω(X) and ∆ based on these identification conditions.
2.3. Estimation. For the rest of the paper, except for Section 2.4, we
will assume a model where trial assignment is correctly specified by (5). We
first estimate ω(X) by solving empirical versions of the proposed moment
conditions. For instance, let α̂1 be the solution to the equation:
(8) N−1
N∑
i=1
ω(Xi − X¯2;α1)I(Ti = 1)(Xi − X¯2) = 0,
where X¯2 = (X¯22N22 + X¯20N20)/(N22 + N20). We use the moment con-
dition from (6) to avoid estimating the additional intercept parameter. The
following result states that α̂1 is consistent and asymptotically linear and
thus also asymptotically normal.
Theorem 2.1 If the trial assignment model is correctly specified by (5),
then α̂1
p→ α∗1, where α∗1 is the true coefficient in (5). Furthermore, α̂1 is
asymptotically linear such that:
(9) N1/2(α̂1 −α∗1) = N−1/2
N∑
i=1
ϕα1i (α
∗
1,µ
∗
X2) + op(1),
where ϕα1i (α1,µX2) = J
α1(α1,µX2)
−1
{
Uα1i (α1,µX2) +U
µX2
i (µX2 ,α1)
}
is a mean zero random vector with finite variance and:
Uα1i (α1,µX2) = (Xi − µX2)exp{αT1 (Xi − µX2)}I(Ti = 1)
U
µX2
i (µX2 ,α1) = −E[exp{αT1 (Xi − µX2)}I(Ti = 1)](Xi − µX2)
I(Ti = 2)
P (Ti = 2)
Jα1(α1,µX2) = −E[(Xi − µX2)(Xi − µX2)Texp{α˜T1 (Xi − µX2)}I(Ti = 1)].
This expansion reveals two sources that contribute to the asymptotic vari-
ance. Suppressing implicit arguments for the parameters, the Uα1i term is
contributed from estimating α1 when µX2 is known. The U
µX2
i term is
the additional contribution when µX2 is considered to be estimated by X¯2.
10
Though this expansion clarifies the sources of variability, the influence func-
tion cannot be directly used to compute the asymptotic variance since U
µX2
i
involves IPD from the AGD trial.
Following estimation of α1, ∆ can subsequently be estimated by an empir-
ical version of (2), plugging in ω(X; α̂1) for ω(X). We consider identification
based on (2) instead of (3) for conciseness of presentation, but similar results
will hold if (3) is used. Specifically, the estimator can be expressed as:
(10)
∆̂ =
N∑
i=1
I(Zi = 1, Ti = 1)ω(Xi; α̂1)Yi/
N∑
i=1
I(Zi = 1, Ti = 1)ω(Xi; α̂1)
− Y¯22.
The following result states that ∆̂ is consistent and asymptotically linear
and thus also asymptotically normal.
Theorem 2.2 Suppose that the identification assumptions (2.1), (2.2), (2.3),
and (2.4) hold and the trial assignment model is correctly specified by (5).
Then ∆̂
p→ ∆∗, where ∆∗ is the true target parameter ∆. Furthermore, ∆̂ is
asymptotically linear such that:
(11) N1/2(∆̂−∆∗) = N−1/2
N∑
i=1
ϕi(∆
∗, µ∗1,α
∗
1,µ
∗
X2) + op(1),
where µ∗1 = E{Y (1)|T = 2} is the true counterfactual mean for the IPD
treatment in the AGD population and ϕi(∆, µ1,α1,µX2) = ϕ
µ2
i (∆, µ1) +
ϕµ1i (µ1,α1) + J
µ1(α1)
−1C˜1(µ1,α1)Tϕα1i (α1,µX2) is a mean zero random
variable with finite variance and:
ϕµ2i (∆, µ1) = (µ1 − Yi −∆)
I(Zi = 2, Ti = 2)
P (Zi = 2, Ti = 2)
ϕµ1i (µ1,α1) = J
µ1(α1)
−1(Yi − µ1)eαT1XiI(Zi = 1, Ti = 1)
Jµ1(α1) = E{eαT1XiI(Zi = 1, Ti = 1)}
C˜1(µ1,α1) = E{Xi(Yi − µ1)eαT1XiI(Zi = 1, Ti = 1)}.
The first ϕµ2i term accounts for estimation of µ
∗
2 = E{Y (2)|T = 2} from Y¯22.
The subsequent terms account for estimating µ∗1 through weighting, which
can be further decomposed into a term contributed for estimating µ∗1 when
α1 is known and another term for estimating α1. Again the asymptotic
variance cannot be directly computed from this influence function because
ϕµ2i and ϕ
α1
i involve the IPD from the AGD trial. We argue in Section 2.4
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that it is often sufficient to compensate for ignoring this term by simply
incorporating the marginal variance of Y¯22 from the AGD trial and consider
other potential strategies.
2.4. Estimation of Asymptotic Variance. To facilitate the subsequent
considerations, we first define the following contributions to the influence
function for ∆̂ for estimating α1 and µX2 :
ϕ˜α1i (α1, µ1,µX2) = J
µ1(α1)
−1C˜1(µ1,α1)TJα1(α1,µX2)
−1Uα1i (α1,µX2)
ϕ˜
µX2
i (µX2 , µ1,α1) = J
µ1(α1)
−1C˜1(µ1,α1)TJα1(α1,µX2)
−1U
µX2
i (α1,µX2).
By calculating the variance of ϕi(∆
∗, µ∗1,α∗1,µ∗X2), the full asymptotic vari-
ance of ∆̂ can now be expressed as:
(12)
σ2 = {V ar(ϕµ1i ) + V ar(ϕµ2i )}+ {V ar(ϕ˜α1i ) + 2Cov(ϕµ1i , ϕ˜α1i )}
+
{
V ar(ϕ˜
µX2
i ) + 2Cov(ϕ
µ2
i , ϕ˜
µX2
i )
}
,
where the arguments of the components of the influence function are sup-
pressed but implicitly evaluated at their respective truth. Decomposing the
variance this way, the first two terms constitutes the asymptotic variance
had α1 been known. The second two terms are contributed from estimating
α1 had µX2 been known, and final two terms account for estimating µX2 .
It is generally not possible to fully estimate σ2 without further assump-
tions as ϕµ2i and ϕ˜
µX2
i involve IPD from the AGD trial. However, it may
still be possible to obtain reasonable approximations. The following lemma
further clarifies the form of the additional contributions from estimating α1
and µX2 under correct identification and modeling assumptions.
Lemma 2.1 Let identification assumptions (2.1), (2.2), (2.3), and (2.4) be
satisfied and the trial assignment model be correctly specified by (5). The
terms contributed from estimating α1 from (12) can be simplified as:
V ar(ϕ˜α1i ) = P (T = 2)
−1CT1 V ar(X|T = 2)−1
E{(X− µ∗X2)(X− µ∗X2)Tω(X)|T = 2}V ar(X|T = 2)−1C1
Cov(ϕµ1i , ϕ˜
α1
i ) = −P (T = 2)−1CT1 V ar(X|T = 2)−1
E{(Y (1)− µ∗1)(X− µ∗X2)ω(X)|T = 2},
where C1 = Cov{Y (1),X|T = 2}. Moreover, the terms contributed for
estimating µX2 from (12) can be simplified as:
V ar(ϕ˜
µX2
i ) = P (T = 2)
−1CT1 V ar(X|T = 2)−1C1
Cov(ϕµ2i , ϕ˜
µX2
i ) = −P (T = 2)−1CT1 V ar(X|T = 2)−1C2,
12
where C2 = Cov{Y (2),X|T = 2}.
As long as there are no strong interactions between X and the treatment, it
can be expected that C1 ≈ C2. In this case, if additionally the trial assign-
ment model is at least approximately correctly specified, then V ar(ϕ˜
µX2
i ) +
2Cov(ϕµ2i , ϕ˜
µX2
i ) ≈ −CT1 V ar(X|T = 2)C1 < 0. Omitting the contributions
from estimating µX2 when estimating σ
2 thus tends to produce conservative
standard errors. By bounding ω(X), a similar phenomenon occurs for terms
contributed from estimating α1 so that V ar(ϕ˜
α1
i ) + 2Cov(ϕ
µ1
i , ϕ˜
α1
i ) < 0
when the trial assignment model is correct and the lower and upper bounds
for ω(X) are not too extreme. These results suggest that omitting contribu-
tions for estimating both α1 and µX2 can yield conservative standard errors
in scenarios where the trial assignment model is correctly specified.
A simple approach to estimating σ2 is thus to estimate only V ar(ϕµ1i )
and V ar(ϕµ2i ), fully omitting contributions for α1 and µX2 , as in:
(13) σ̂2fo = V̂ ar {ϕµ1i (µ̂1, α̂1)}+ V̂ ar
{
ϕµ2i (∆̂, µ̂1)
}
,
where µ̂1 is the weighted average from the IPD as in the first term of (10),
V̂ ar {ϕµ1i (µ̂1, α̂1)} is the sample variance of ϕµ1i (µ̂1, α̂1), and V̂ ar
{
ϕµ˜2i (∆̂, µ̂1)
}
=
S2Y,22/(N22/N). Previous approaches to estimating standard errors for MAIC
using robust sandwich estimators (Signorovitch et al., 2010; Phillippo et al.,
2016), which are sometimes utilized in practice, are similar to this approach
in that they ignore the variability from estimating α1 and µX2 . Instead of
fully ignoring the contributions for both α1 and µX2 , another approach is
to partially omit only the contribution for µX2 , as in:
(14) σ̂2po = V̂ ar
{
ϕµ1i (µ̂1, α̂1) + ϕ˜
α1
i (α̂1, µ̂1, µ̂X2)
}
+ V̂ ar
{
ϕµ2i (∆̂, µ̂1)
}
,
where µ̂X2 = X¯2. This is still feasible as ϕ˜
α1
i does not involve IPD from
the AGD trial. A final approach is to attempt to fully estimate σ2. Without
any further assumptions, V ar(ϕ˜
µX2
i ) can be approximated by:
V µX2 = −E{e
α∗T1 (Xi−µ∗X2 )I(Ti = 1)}
Jµ1(α∗1)2P (Ti = 2)
C˜1(α
∗
1)
TJα
∗
1(α∗1,µ
∗
X2)
−1C˜1(α∗1),
which partially simplifies V ar(ϕ
µ˜X2
i ) under correct trial selection model
to obviate the need for IPD from the AGD trial. The covariance term
Cov(ϕµ2i , ϕ˜
µX2
i ) can be bounded by the Cauchy-Schwartz inequality. This
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suggests estimating σ2 by:
(15)
σ̂2cs = V̂ ar
{
ϕµ1i (µ̂1, α̂1) + ϕ˜
α1
i (α̂1, µ̂1, µ̂X2)
}
+ V̂ ar
{
ϕµ2i (∆̂, µ̂1)
}
+ V̂ µX2 + 2
[
V̂ ar
{
ϕµ2i (∆̂, µ̂1)
}
V̂ µX2
]1/2
,
where V̂ µX2 is an empirical version of V µX2 . Among these proposed ap-
proaches, we expect σ̂2fo to be more conservative than σ̂
2
po as it potentially
omits negative contributions to the asymptotic variance when underlying
assumptions are satisfied. We will see in the simulation results of Section 3
that this conservativeness of σ̂2fo tends to improve its accuracy in approx-
imating the true standard error in small samples, when both σ̂2fo and σ̂
2
po
tend to underestimate, without paying a large price in terms of overestima-
tion in large samples. Such underestimation in small samples has also been
observed for sandwich variance estimators in other settings(Kauermann and
Carroll, 2001; Fay and Graubard, 2001). σ̂2cs can be expected to be the most
conservative, as it uses a very conservative bound for covariance. This esti-
mator could be potentially useful in situations when conservative confidence
intervals and hypothesis tests are prioritized over efficiency considerations.
2.5. Alternative Sampling Schemes. A way to avoid the issue of the lack
of full IPD when estimating the standard error of ∆̂ is to consider µ∗X2 and
µ∗2 as fixed parameters. That is, one may consider µ∗X2 = X¯2 or µ
∗
2 = Y¯22.
Under either of these assumptions, the asymptotic variance σ2 would exclude
terms involving either ϕ˜
µX2
i or ϕ
µ2
i , respectively. Inference based on these
assumptions clearly then would not acknowledge sampling variability from
estimating these parameters, which may or may not be justified depending
on the context of the problem. In this article we primarily focus on the more
difficult case where estimates from the AGD are considered to be random.
A related point is that the allocation of patients among trials in practice
may be constrained such that each trial and arm enrolls a fixed, or nearly
fixed, number of patients. While formally this sampling scheme differs from
the problem setup, which does not assume any sample size constraints, it can
be accommodated as a simple extension that does not impact the asymptotic
analysis. In particular, one could consider patients to be sub-sampled by
trial and arm to meet size constraints after initially being sampled without
constraint from the super-population. Under the assumptions on the initial
sample required when sampling without constraint, the proposed procedures
for inference about ∆ based on ∆̂ would still be valid using the sub-sampled
data as long as the sub-sampling was random by trial and arm.
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More concretely, suppose N∗ total patients were initially sampled without
constraint. Let Ri ∈ {0, 1} for i = 1, . . . , N∗ be an indicator of whether each
patient is sub-sampled into the final sample. If a fixed ntz number of patients
were enrolled into arm z of trial t, the constraint on the sub-sampling is that∑N∗
i=1RiI(Ti = t, Zi = z) = ntz, for t = 1, 2 and z = 0, 1, 2. If sub-sampling
was random by trial and arm, then:
(16) R ⊥⊥ {X, Y (0), Y (1), Y (2)}|T,Z.
When Assumption 2.1 holds in the initial sample, then we also have that
R ⊥⊥ {X, Y (0), Y (1), Y (2)}|T . But under this independence:
E{Y (2)|T = 2} = E{Y (2)|T = 2, R = 1}, and
E{Y (1)|T = 2} = E{Y (1)|T = 2, R = 1}.
Moreover, Assumptions 2.1-2.4 can be shown to still hold conditional on
R = 1, provided they hold in the initial sample. The same arguments to
identify ∆ from Section 2.2 thus hold under distributions that are conditional
on R = 1. ∆̂ will then be consistent for ∆ when the sub-sampled data is
used, if ω(X) among the sub-sampled data can be identified and estimated.
But if trial assignment among the initial sample follows a logistic regression
model as in (5), then:
logitP (T = 2|X, R = 1) = αTT
−→
X,
where αT = (α0,T ,α1). That is, the trial assignment among the sub-sample
still follows a logistic regression model with a possibly different intercept
α0,T . This is analogous to the result that the probability of an outcome
given covariates among those sampled in a case-control study still follows
the same logistic regression with a different intercept when the prospective
model is logistic regression (Prentice and Pyke, 1979). The arguments for
identification of ω(X) in Sections 2.2 are thus also still valid, and estimation
can proceed from solving (8) among the sub-sampled data.
3. Simulations. We performed simulations to assess the finite sample
bias of MAIC and alternative estimators. In particular, we sought to identify
scenarios where proposed approaches fail to provide reliable inferences. We
also assessed the coverage and relative length of CIs based on the proposed
variance estimators. Besides the estimator ∆̂ (MAIC-NAB), which is based
on (2), we also consider an anchored MAIC approach (MAIC-ACB) based on
(3), ∆̂ACB = ∆̂ − {∑Ni=1 I(Zi = 0, Ti = 1)ω(Xi; α̂1)Yi/∑Ni=1 I(Zi = 0, Ti =
1)ω(Xi; α̂1) − Y¯20}. Additionally, we consider the method of Bucher et al.
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(1997) (BUC) and the basic formulation of simulated treatment comparisons
of Ishak, Proskorovsky and Benedict (2015) (STC). To be consistent in the
scale of contrast with other methods, we implement BUC on the risk differ-
ence scale as ∆̂BUC = (Y¯11− Y¯10)− (Y¯22− Y¯20). As such, BUC would require
that E(Y |Z,X) be linear in X to be unbiased, where X are covariates that
satisfy Assumption 2.5. We also considered simulations for contrasts on the
log odds-ratio scale for all methods in Appendix B. For STCs, we assume a
logistic regression model for E(Y |Z = 1,X):
m1(X;γ) = g(γ
T−→X),
where g(·) denotes the inverse-logit link function for binary outcomes in
the simulations. This model is fit using data from active arm in the IPD
trial, with the estimator denoted by γ̂. It is then used to extrapolate the
mean outcome had individuals in the AGD trial received treatment Z = 1
by ∆̂STC = m1(X¯2; γ̂)− Y¯22. This approach would be unbiased if the model
for E(Y |Z = 1,X) is correctly specified with g(·) being linear. But even if
m1(X;γ) is correctly specified and X satisfy the identification assumptions,
still E{Y (1)|T = 2} = E{E(Y |Z = 1,X)|T = 2} 6= E{Y |Z = 1,X =
E(X|T = 2)} = m(µX2 ;γ) when g(·) is non-linear, which results in bias.
We simulated data jointly for both the IPD and AGD trials in the case
with binary Y and continuous X. In all scenarios, independent observations
were simulated according to X ∼ N(0, .8Ip+.2), T |X ∼ Ber{P (T = 2|X)}+
1, Z ∼ Ber(.5) · T , and Y |X, Z, T ∼ Ber{E(Y |X, Z, T )}, where:
(17)
logitP (T = 2|X) = α0 +αT1X
logitE(Y |X, Z, T ) = β0 + {βT1 + βT3 I(Z > 0)}X+ β2I(Z > 0) + I(Z = 2)β4,
with α0 = 0 β0 = −1, β2 = .1, and β4 = .5. For P (T = 2|X), α1 6= 0 induces
imbalance in the distribution of X in the IPD and AGD trial populations.
Any imbalance in a subvector of X that also has a non-zero coefficient in β3
subsequently induces confounding when comparing outcomes between trials.
β3 6= 0 results in treatment effect heterogeneity on the logit scale between
active and placebo treatments. We considered scenarios with no confound-
ing, moderate confounding, and severe confounding, with the parameters:
None: α1 = (.251
T
4 ,0
T
p−4)
T β1 = 0p β3 = 0p
Moderate: α1 = (.251
T
4 ,0
T
p−4)
T β1 = (.151
T
4 ,0
T
p−4)
T β3 = (.11
T
4 ,0
T
p−4)
T
Severe: α1 = (.301
T
4 ,0
T
p−4)
T β1 = (.251
T
4 ,0
T
p−4)
T β3 = (.151
T
4 ,0
T
p−4)
T.
We initially generated a large sample {(Yi, Zi, Ti,Xi) : i = 1, . . . , N∗} and
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then randomly sub-sampled by arm in each trial, as described in Section 2.5,
to include a fixed number of n patients in all arms in the final sample.
In each replicate of the data we calculated the the four estimators for
∆, as well as the four estimators for σ2 discussed in Section 2.4. Besides
σ̂2fo, σ̂
2
po, and σ̂
2
cs, we also implemented an estimator σ̂
2
sw based on a sand-
wich estimator for regression coefficients when ∆̂ is implemented through a
weighted linear regression, using the sandwich package in R with default op-
tions (Zeileis, 2004). The approach has been previously considered for ∆̂ACB
(Phillippo et al., 2016) and is essentially a direct calculation of the variance
of ∆̂, treating the weights ω(Xi) and treatment assignment Ti as fixed and
plugging in estimators for the variance of Yi that allow for heteroskedasticity.
For benchmarking purposes, we also calculated an estimator of σ2 using the
full influence function, the estimator that would typically be computed had
the IPD from all trials been available. The true ∆ was calculated through
simulating a large sample and calculating the mean difference of counter-
factual outcomes had patients in the AGD population received treatment
Z = 1 and Z = 2, according to E(Y |X, Z, T ) in (17). The percent bias
for each estimator was then calculated as R−1
∑R
r=1(∆̂
(r) − ∆)/∆, where
∆̂(r) denotes an estimator calculated from data in the r-th replicate. The
bias simulations were repeated over the different confounding scenarios for
sample sizes ranging n = 25 to n = 500 per arm and p = 5, 10, 15. The CI
coverage was calculated as R−1
∑R
r=1 I[∆ ∈ {∆̂(r)± z.975N−1/2σ̂(r)}], where
z.975 denotes the .975 quantile of a standard normal and σ̂
(r) denotes an es-
timator of the asymptotic variance estimated from data observed in the r-th
replicate. Relative CI length was calculated as R−1
∑R
r=1 σ̂
(r)/σ̂emp, where
σ̂2emp = (R − 1)−1
∑R
r=1{∆̂(r) − R−1
∑R
r=1 ∆̂
(r)}2 is the empirical variance
of ∆̂(r) over all repetitions. The coverage simulations were conducted under
the moderate confounding scenario for n = 25 to n = 500 per arm with
p = 5, 15. For each set of simulations we ran R = 5, 000 replicates to well
approximate the tail probabilities when evaluating CI coverage.
3.1. Simulation Results. The results for the bias simulations are pre-
sented in Table 2. Both MAIC estimators generally exhibited negligible bias
across the scenarios considered. The bias of BUC increases with the degree of
confounding and results from the non-linear link function for E(Y |X, Z, T )
and interaction between X and Z in (17). Similar results hold even when
considering contrasts on the log odds-ratio scale in Appendix B. STC also
incurred bias that increases with the degree of confounding due to the non-
linear link. STC, however, generally had lower bias than BUC for larger
n. Extrapolation based on fitting m1(X;γ) appears to outperform placebo
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adjustment in BUC in large samples. The bias of STC in small samples also
appears to be more sensitive to increasing p than MAIC and BUC.
Table 2
Percent bias of estimators by degree of confounding, sample size per arm (n), and
number of covariates (p).
No Confounding Moderate Confounding Severe Confounding
Size Estimator p=5 p=10 p=15 p=5 p=10 p=15 p=5 p=10 p=15
n=25
BUC -2% 1% 3% 28% 24% 28% 43% 40% 42%
STC 41% 95% 96% 53% 104% 93% 51% 84% 82%
MAIC-NAB -1% -1% 0% 5% 2% 7% 5% 5% 10%
MAIC-ACB -3% 0% -1% 3% 0% 6% 0% 1% 5%
n=50
BUC -1% 0% 1% 26% 26% 28% 46% 44% 43%
STC 18% 46% 90% 28% 57% 107% 37% 68% 113%
MAIC-NAB 0% 0% 0% 1% 1% 3% 5% 4% 4%
MAIC-ACB -1% 0% 2% 1% 0% 3% 5% 2% 2%
n=100
BUC 0% 0% 0% 27% 27% 25% 43% 44% 44%
STC 8% 21% 33% 20% 31% 43% 27% 38% 51%
MAIC-NAB -1% 1% 0% 2% 2% 0% 1% 2% 3%
MAIC-ACB 0% 0% 0% 1% 1% -1% -1% 1% 2%
n=250
BUC -1% 0% 0% 26% 27% 27% 44% 44% 44%
STC 3% 8% 12% 14% 18% 22% 23% 27% 31%
MAIC-NAB 0% 0% 0% 0% 0% 1% 1% 1% 2%
MAIC-ACB 0% 0% 1% -1% 0% 0% 1% 1% 1%
n=500
BUC 1% 0% -1% 27% 26% 27% 43% 44% 43%
STC 2% 3% 6% 13% 14% 16% 21% 24% 24%
MAIC-NAB 0% 0% 0% 0% 0% 0% 0% 1% 0%
MAIC-ACB 0% 0% 0% 1% 0% 1% 0% 1% 0%
BUC: Method of Bucher et al, STC: Simulated treatment comparison, MAIC-NAB:
Non-anchor-based MAIC, MAIC-ACB: Anchor-based MAIC.
Results from the coverage simulations are presented in Figure 1. CIs based
on σ̂2fo and σ̂
2
sw generally achieve close to nominal coverage for n ≥ 50
per arm. They are only slightly conservative in terms of both coverage and
length, relative to empirical estimates, in large samples. Approximating the
behavior of CIs based on the full influence function, CIs based on σ̂2po also
achieve close to nominal coverage for n ≥ 150 per arm when p = 5 but
exhibits slight undercoverage for smaller n and when p = 15. This could
be related to underestimation observed for sandwich estimators in small
samples as discussed in Section 2.4 and can be expected with larger number
of parameters. Still, in large samples both still show excellent performance.
For all the approaches considered, there appears to be a drop in coverage
for n = 25. CIs for studies with such small samples should be interpreted
with caution. The CI based on σ̂2cs is consistently conservative, achieving
coverage of around 97% in most scenarios and exhibiting a length around
5-10% longer than CIs based on empirical estimates of the standard error.
In the Supplementary Materials, we also provide an extended set of simu-
lation results on both bias and coverage for a range of data settings, including
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Fig 1. Coverage and relative length of 95% CI’s for ∆̂ by size per arm (n) and number of
covariates (p) in the moderate confounding scenario. Some points and bars for n = 25 are
omitted if they take values beyond the axis limits. σ̂2fo and σ̂
2
sw achieve close to nominal
coverage for n ≥ 50 and only slightly conservative in length.
Full: Based on full influence function, Sig2-CS: Based on σ̂2cs, Sig2-PO: Based on σ̂
2
po,
Sig2-FO: Based on σ̂2fo, Sig2-SW: Based on σ̂
2
sw.
for both binary and continuous Y , to further elucidate when MAIC and its
standard error estimators are or are not reliable.
4. Data Application. Duchenne muscular dystrophy (DMD) is a rare
neuromuscular disorder in which patients experience progressive muscle de-
generation that often leads to loss of ambulation during adolescence, respira-
tory and cardiac dysfunction in early adulthood, and eventually premature
mortality (Emery, Muntoni and Quinlivan, 2015). Due to the rarity of the
disease, recruitment of DMD patients into clinical trials can be challenging.
There is strong interest in adopting single-arm designs for future DMD tri-
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als and using natural history (NH) data for external controls. Such external
control groups have previously informed drug approval in other rare diseases
(ICH, 2000; FDA, 2006, 2017). However, indirect comparisons to external
controls is subject to the risk of bias due to potential differences in patient
baseline characteristics, along with other factors such as those in Table 1.
To illustrate MAIC, we considered a “negative control study to assess
whether a NH cohort from a prospective non-interventional study (DMD-
PRO-01), provided by CureDuchenne, a 501(3)c patient foundation, are suf-
ficiently comparable to the placebo arm of a phase III DMD trial for tadalafil
(PBO), provided by Eli Lilly, using IPD from DMD-PRO-01 and AGD from
the PBO trial. If the NH setting is sufficiently comparable to the trial, mean
outcomes between the studies should be similar after adjustment for dif-
ferences in observed characteristics. The data were accessed through the
Collaborative Trajectory Analysis Project (cTAP), a collaboration aiming
to improve clinical trial design and interpretation in DMD.
We focused on a binary outcome for clinically significant worsening of
the North Star Ambulatory Assessment (NSAA), defined as decrease of ≥ 3
units from baseline to week 48 after study initiation (Ricotti et al., 2016).
We implemented MAIC-NAB, in addition to STC and a nave comparison
that directly contrasted mean outcomes between the two studies without
adjustment for baseline characteristics. Comparisons were conducted on the
log odds-ratio scale. For instance, MAIC-NAB estimates are obtained as
∆̂g = g(µ̂1) − g(Y¯22) with g(u) = log{u/(1 − u)}. For MAIC and STC,
we include baseline characteristics from Table 3 in X. Estimators of the
asymptotic variance on the log-odds ratio scale based on strategies discussed
in Section 2.4 were obtained (detailed in Appendix A). We report SEs based
on σ̂2fo, which we chose since the sample size is not small. For the nave
comparison, we use the usual SE estimator for log odds-ratios based on
the delta method (Bland and Altman, 2000). Only the point estimate is
reported for STC. Two-sided p-values were also reported from Wald tests
for the null hypothesis that there is no difference in the proportion of patients
with NSAA worsening between studies. Comparisons were repeated with and
without application of the inclusion/exclusion criteria from the tadalafil trial
to DMD-PRO-01 (age 7-14 years, steroid duration ≥ 6 months, baseline 6
min walk distance 200-400 meters).
Table 3 reports the key characteristics available in both cohorts. Patients
in the NH cohort, on average, were younger, had better ambulatory func-
tion and rise time, and shorter duration of steroid treatment. The indirect
comparison results are reported in Table 4. A nave comparison of outcomes
suggests that there were significant differences in NSAA worsening, with
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odds of worsening about 40% lower in NH vs. PBO (OR=0.58; 95% CI: 0.34
to 0.99, p = 0.04). After MAIC adjustment, the magnitude of differences
attenuated and was no longer statistically significant (OR = 1.14, 95% CI:
0.64 to 2.04, p = 0.66). The standard error increased slightly on the log odds
scale from 0.27 to 0.30 after adjustment with MAIC. Results were similar
for STC (OR=1.20). Findings were also similar after applying the trial in-
clusion/exclusion criteria. These results suggest that NH data is comparable
to trial data after appropriate adjustment for baseline characteristics.
Table 3
Baseline characteristics of patients from DMD-PRO-01 (NH) and tadalafil trial (PBO).
Baseline Characteristics NH (n=152) PBO (n=90)
Age (years) 8.8 9.3
NSAA score 24.4 22.6
Six min walk distance (meters) 374.3 348.5
Rise time ≥ 5 seconds 50.0% 74.4%
Steroid duration ≥ 12 months 70% 90%
Height (cm) 122.1 125.5
Weight (kg) 28.2 30.6
NSAA: North Star Ambulatory Assessment
Table 4
Indirect comparison of NSAA worsening between NH vs. PBO cohorts.
Method OR 95% CI Log OR SE p-value
No inclusion/exclusion
criteria applied
Naive 0.58 (0.34, 0.99) -0.54 0.27 0.04
STC 1.20 - 0.19 - -
MAIC-NAB 1.14 (0.64, 2.04) 0.13 0.3 0.66
With inclusion/exclusion
criteria applied
Naive 1.78 (0.95, 3.34) 0.58 0.32 0.07
STC 1.75 - 0.56 - -
MAIC-NAB 1.42 (0.69, 2.92) 0.35 0.37 0.34
Naive: Unadjusted comparison, STC: Simulated treatment comparison, MAIC-NAB:
Non-anchor-baed MAIC.
5. Discussion. As with any nonrandomized treatment comparison, in-
direct comparisons through MAIC can be biased by differences in unobserved
confounders. Researchers ought to include covariates X such that Assump-
tions 2.4 or 2.5 are satisfied as much as possible and recognize the limitations
of indirect comparison when confounders are unobserved. In the literature on
estimating average treatment effects, it is well-known that including covari-
ates associated with only the outcome increases efficiency, while covariates
associated with only the exposure decreases efficiency (Lunceford and Da-
vidian, 2004; Brookhart et al., 2006; Rotnitzky, Li and Li, 2010; De Luna,
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Waernbaum and Richardson, 2011). The same results are expected to hold
when estimating the weights for MAIC, viewing trial selection as the “ex-
posure.” It is thus generally advisable to include in X observed covariates
that are known or suspected to be associated with outcomes, even if their
imbalance between trials is minor (Rubin and Thomas, 1996; Lunceford and
Davidian, 2004; Stuart, 2010). As discussed in Section 2.2, with anchor-based
MAIC, there are cases where it is not necessary to adjust for covariates in X
that are not effect modifiers. However, it is generally difficult to be certain
that any covariate is not an effect modifier, especially for novel therapies. A
simple objective approach to covariate selection is to include all covariates
available for both the IPD and AGD that cannot be ruled out as having
no associations with outcomes. Known prognostic covariates that are unob-
served should be noted among the limitations. Sensitivity analyses on the
impact of adding or removing covariates from X can also be informative.
Even when all confounders are observed, MAIC still relies on the trial
assignment model from (5) being at least approximately correct for a given
X to make appropriate adjustments. It is important for researchers to con-
sider its specification, such as whether higher-order polynomial or interaction
terms are plausible and the corresponding requisite AGD, such as standard
errors or correlations, are available. Other parametric models besides logistic
regression could also be used, but the estimating equation that balances trial
covariates, as in (4), must admit a unique solution for the model parameters.
Beyond unobserved confounding and model specification, Assumption 2.3
is also an important assumption. When P (T = 1|X = x) is close to 0 for
some x ∈ X , there exist some subpopulation in the AGD population that
does not have strong overlap with the IPD population. This leads some
observations in the IPD to receive extreme weights and dominate the re-
weighted sample, resulting in poor performance in point and standard error
estimation. A useful diagnostic tool for lack of overlap is the effective sample
size, defined by N˜1z = {∑Ti=1,Zi=z ω(Xi; α̂1)}2/∑Ti=1,Zi=z ω(Xi; α̂1)2 for
weighted samples from arm z = 0, 1 of the IPD. N˜1z is an approximation
from importance sampling that down-weights the sample size by the approx-
imate relative efficiency between a sample average using data from a target
distribution and and a weighted average from a proposal distribution (Kong,
1992). Violations or near-violations of Assumption 2.3 would tend to inflate
some ω(Xi; α̂1) and deflate N˜1z, signaling poor overlap. In simulations,
coverage in cases when N˜11 ≤ p ranged 68-88% for CIs based on σ̂2fo, in the
small sample scenario with n = 25, p = 5, 15, and moderate confounding.
This suggests that inferences based on ∆̂ are suspect in real datasets when
N˜11 is less than or close to p. While N˜1z is termed the “effective sample size”
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for arm z = 0, 1, it has no direct bearing on statistical inferences, including
standard error and CI estimation, and should be viewed as a rough indica-
tor only. Poor performance in estimation can also result when p is large or
covariates in X are heavily correlated, which yields large standard errors for
α̂1. One possible remedy would be to add a regularization term to (8).
As illustrated in Section 4, it is possible to consider a non-definitive test
for the adequacy of Assumptions 2.1-2.4 and specification of trial selection
model using data from a common comparator arm, if available, provided the
studies are deemed to be sufficiently similar in other aspects. Let
∆̂0 =
N∑
i=1
I(Zi = 0, Ti = 1)ω(Xi; α̂1)Yi/
N∑
i=1
I(Zi = 0, Ti = 1)ω(Xi; α̂1)
− Y¯20
denote the difference in outcomes under the common comparator after
weighting. Under the null that these assumptions hold, N1/2∆̂0
d→ N(0, σ20),
where σ20 is analogous to σ
2 for outcomes under the common comparator.
Consequently a test that rejects when N1/2|∆̂0|/σ̂0 > z1−α/2 is a level α test,
where σ̂20 is an estimator of σ
2
0 that can be constructed using similar strate-
gies as in Section 2.4. The type I error may be conservative if a conservative
strategy for estimating σ20 is used. Rejection in such a test suggests violation
of some assumption, but failure to reject does not verify the assumptions.
For instance, there may be unobserved confounders that impact outcomes
in the active treatment arms but not for the placebo arm.
Another direction of future research will be to consider efficient estima-
tion of ∆. In particular, it would be of interest to consider whether any
estimator with only AGD available in one trial can still achieve the known
semiparametric efficiency bound for ∆ (Hahn, 1998). Recently, entropy bal-
ancing, a method that estimates causal effects via weights that minimize the
relative entropy with the distribution of covariates in the control population,
has been shown to be locally semiparametric efficient if the propensity score
model and mean outcomes in the treated population are both linear in the
covariates X (Zhao and Percival, 2017). Moreover, it was be also shown
to be doubly robust in that it is consistent if either the propensity score
model or outcome model is linear in X. Since entropy-balancing coincides
with ∆̂ when a logistic regression model is used for trial assignment, this
immediately indicates that MAIC is also locally semiparametric efficient and
doubly robust in the same sense. It would be of interest to consider whether
doubly robust and efficient estimators are available for more general models
when full IPD has been withheld for one treatment group. Developments of
extensions for MAIC along these lines are underway.
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APPENDIX A: INFERENCES ON NON-LINEAR SCALE
When the treatment effect on a different scale of contrast is of interest,
∆g can be estimated by first estimating E{Y (1)|T = 2} and E{Y (2)|T = 2}
and then applying a specified g(·) transformation. The same considerations
for identification and estimation of E{Y (1)|T = 2} and E{Y (2)|T = 2}
applies as in Sections 2.2 and 2.3. The estimator in this case would then be:
(18) ∆̂g = g(µ̂1)− g(Y¯22),
where µ̂1 is the weighted average for treatment 1 using the IPD.
Applying the delta method, when g(u) is differentiable and non-zero val-
ued at u = µ1 and u = µ2, the influence function for ∆̂gis given by:
N1/2(∆̂g −∆g) = N−1/2
N∑
i=1
ψµ2i (∆
∗, µ∗1) + ψ
µ1
i (µ
∗
1,α
∗
1)
+ ψ˜α1i (α
∗
1, µ
∗
1,µ
∗
X2) + ψ˜
µX2
i (α
∗
1, µ
∗
1,µ
∗
X2) + op(1),
where:
ψµ2i (∆, µ1) = ϕ
µ2
i (∆, µ1)g
′(µ1 −∆)
ψµ1i (µ1,α1) = ϕ
µ1
i (µ1,α1)g
′(µ1)
ψ˜α1i (α1, µ1,µX2)
= Jµ1(α1)
−1C˜1(µ1,α1)TJα1(α1,µX2)
−1Uα1i (α1,µX2)g
′(µ1)
ψ˜
µX2
i (α1, µ1,µX2)
= Jµ1(α1)
−1C˜1(µ1,α1)TJα1(α1,µX2)
−1U
µX2
i (α1,µX2)g
′(µ1)
are modifications of the original influence function with g′(u) = ∂∂ug(u). In
parallel to (12), the asymptotic variance of ∆̂g can be expressed as:
(19)
σ2g = {V ar(ψµ1i ) + V ar(ψµ2i )}+ {V ar(ψ˜α1i ) + 2Cov(ψµ1i , ψ˜α1i )}
+ {V ar(ψ˜µX2i ) + 2Cov(ψµ2i , ψ˜
µX2
i )},
where the arguments of the components of the influence function are sup-
pressed but implicitly evaluated at their respective truth. Based on similar
considerations, the three proposed estimators for σ2g are:
(20)
σ̂2g,fo = V̂ ar{ψµ1i (µ̂1, α̂1)}+ V̂ ar{ψµ2i (∆̂, µ̂1)}
σ̂2g,po = V̂ ar{ψµ1i (µ̂1, α̂1)}+ V̂ ar{ψ˜α1i (α̂1, µ̂1, µ̂X2)}+ V̂ ar{ψµ2i (∆̂, µ̂1)}
σ̂2g,cs = V̂ ar
{
ψµ1i (µ̂1, α̂1) + ψ˜
α1
i (α̂1, µ̂1, µ̂X2)
}
+ V̂ ar{ψµ2i (∆̂, µ̂1)}
+ V̂ µX2g′(µ̂1)2 + 2[V̂ ar{ψµ2i (∆̂, µ̂1)}V̂ µX2g′(µ̂1)2]1/2.
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As in Section 2.4, σ̂2g,fo tends to outperform σ̂
2
g,po in small samples, whereas
σ̂2g,cs provides a conservative estimate.
APPENDIX B: SIMULATION RESULTS ON LOGIT SCALE
We repeated the simulations to assess the bias of the corresponding es-
timators modified to estimate the treatment effect on the logit scale, i.e.
∆g with g(u) = log{u/(1− u)}. This has previously been the recommended
scale for binary outcomes HTA applications (Phillippo et al., 2016). The
performance of CIs for MAIC-NAB based on the modified estimators of
the asymptotic variance were also assessed. The same simulation settings as
those in Section 3 were used throughout. MAIC-ACB was calculated based
on ∆̂ACBg = ∆̂g − g{
∑N
i=1 I(Zi = 0, Ti = 1)ω(Xi; α̂1)Yi/
∑N
i=1 I(Zi = 0, Ti =
1)ω(Xi; α̂1)}+ g(Y¯20).
The bias results are reported in Table 5. Similar patterns of bias occur
as when estimating ∆. BUC and STC incur substantial bias in scenarios
with confounding, whereas MAIC has negligible bias except with extremely
low sample size case with n = 25 per arm where no method is reliable. The
CI performance results are presented in Figure 2. CIs based on σ̂2g,fo and
σ̂2g,sw achieve near nominal coverage when n ≥ 50 per arm and their lengths
do not surpass those based on the empirical estimate by more than 5% for
most n. CIs based on σ̂2g,po exhibit good coverage when sample size is large
relative to p but tends to undercover when n is relatively small. CIs based
on σ̂2g,cs are the most conservative.
APPENDIX C: PROOFS OF THEOREMS
C.1. Proof of Theorem 2.1. Let the estimating equation from (8) be
denoted:
(21) Uα1N (α1,µX2) = N
−1
N∑
i=1
exp{αT1 (Xi − µX2)}(Xi − µX2)I(Ti = 1).
We will first outline the consistency of α̂1 for α
∗
1. It can be shown that
there exists a CN = Op(1) such that:
(22)
sup
α1
∥∥∥Uα1N (α1, µ̂X2)−Uα˜1,1N (α1,µ∗X2)∥∥∥ ≤ CN ∥∥µ̂X2 − µ∗X2∥∥
= op(1),
by using that Uα1N (α1,µX2) is continuously differentiable in µX2 , the pa-
rameter space for (αT1 ,µ
T
X2
)T, denoted by Θ, is compact, and µ̂X2 is a
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Table 5
Percent bias of estimators of ∆g by degree of confounding, total size (N), and number of
covariates (p).
No Confounding Moderate Confounding Severe Confounding
Size Estimator p=5 p=10 p=15 p=5 p=10 p=15 p=5 p=10 p=15
n = 25
BUC 5% 3% 2% 36% 32% 41% 50% 45% 53%
STC 1315% 11064% 3752% 1816% 9903% 3392% 2498% 9066% 2951%
MAIC-NAB 14% 27% 365% 20% 24% 322% 23% 41% 362%
MAIC-ACB 0% -7% -122% 4% -11% -44% -3% 2% -173%
n = 50
BUC 3% 2% 0% 28% 32% 33% 44% 42% 47%
STC 31% 146% 10724% 42% 346% 11908% 53% 702% 11294%
MAIC-NAB 4% 8% 6% 7% 9% 15% 7% 10% 10%
MAIC-ACB 3% 0% -4% 0% 4% 7% -1% -2% 0%
n = 100
BUC 3% 2% -1% 30% 29% 28% 44% 46% 46%
STC 14% 28% 66% 23% 38% 101% 33% 45% 209%
MAIC-NAB 3% 3% 2% 3% 4% 4% 6% 3% 6%
MAIC-ACB 3% 1% -1% 2% 2% 1% 1% 2% 2%
n = 250
BUC 1% 2% 1% 29% 29% 27% 42% 44% 46%
STC 6% 10% 21% 17% 21% 29% 23% 29% 39%
MAIC-NAB 2% 2% 2% 2% 2% 1% 0% 2% 2%
MAIC-ACB 1% 2% 0% 1% 2% 0% -2% 1% 2%
n = 500
BUC 0% 0% 1% 28% 27% 28% 41% 43% 44%
STC 3% 5% 9% 14% 16% 21% 21% 25% 29%
MAIC-NAB 1% 1% 1% 1% 0% 1% -1% 1% 2%
MAIC-ACB 0% 0% 1% 0% -1% 1% -2% 0% 1%
BUC: Method of Bucher et al, STC: Simulated treatment comparison, MAIC-NAB:
Non-anchor-based MAIC, MAIC-ACB: Anchor-based MAIC.
consistent estimator for µ∗X2 . Let Θα1 be the parameter space for α1. More-
over, it can be shown that there exists a DN = Op(1) such that for any˜˜α1, α˜1 ∈ Θα1 :
(23)
∥∥∥Uα1N ( ˜˜α1,µ∗X2)−Uα1N (α˜1,µ∗X2)∥∥∥ ≤ DN ∥∥∥ ˜˜α1 − α˜1∥∥∥ ,
using that Uα1N (α1,µ
∗
X2
) is continuously differentiable in α1 and Θα1 is
compact. Let Uα1(α1,µX2) = E[exp{αT1 (Xi −µX2)}(Xi −µX2)I(Ti = 1)].
Since Uα1N (α1,µ
∗
X2
)
p→ Uα1(α1,µ∗X2) pointwise for each α1 ∈ Θα1 , we have:
(24) sup
α1
∥∥Uα1N (α1,µ∗X2)−Uα1(α1,µ∗X2)∥∥ = op(1)
using Lemma 2.9 of Newey and McFadden (1994). This verifies that:
(25)
sup
α1
∥∥Uα1N (α1, µ̂X2)−Uα1(α1,µ∗X2)∥∥
≤ sup
α1
∥∥Uα1N (α1, µ̂X2)−Uα1N (α1,µ∗X2)∥∥+ sup
α1
∥∥Uα1N (α1,µ∗X2)−Uα1(α1,µ∗X2)∥∥
= op(1).
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Fig 2. Coverage and relative length of 95% CI’s for ∆̂ by size per arm (n) and number
of covariates (p) in the moderate confounding scenario. Some points and bars for n = 25
are omitted if they take values beyond the axis limits.
Full: Based on full influence function, Sig2-CS: Based on σ̂2g,cs, Sig2-PO: Based on σ̂
2
g,po,
Sig2-FO: Based on σ̂2g,fo, Sig2-SW: Based on σ̂
2
g,sw.
Now since E[exp{αT1 (Xi−µX2)}I(Ti = 1)] is strictly convex inα1,Uα1(α1,µX2)
has a unique solution in α˜1 for a given µX2 . Hence α̂1
p→ α∗1 by Theorem 5.9
of Van der Vaart (2000). We now turn to obtaining the influence function
for α̂1. Let U
α1
N,j(α1,µX2) denote the j-th component of U
α1
N (α1,µX2), for
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j = 1, . . . , p. An expansion of Uα1N,j(α̂1, µ̂X2) around (α
∗
1,µ
∗
X2
) yields:
(26)
Uα1N,j(α̂1, µ̂X2) = U
α1
N,j(α
∗
1,µ
∗
X2) +
∂
∂α
T
1
Uα1N,j(α
∗
1,µ
∗
X2)(α̂1 −α∗1)
+
∂
∂µTX2
Uα1N,j(α
∗
1,µ
∗
X2)(µ̂X2 − µ∗X2) +
∂2
∂α⊗21
Uα1N,j(α˜1,µ
∗
X2)(α̂1 −α∗1)⊗2
+
∂2
∂µ⊗2X2
Uα1N,j(α̂1, µ˜X2)(µ̂X2 − µ∗X2)⊗2 +
∂2
∂α1∂µX2
Uα1N,j(
˜˜α1,µ∗X2)(α̂1 −α∗1)(µ̂X2 − µ∗X2),
where α˜1 and ˜˜α1 are intermediates on the line segment between α̂1 and α∗1,
and µ˜X2 is an intermediate between µ̂X2 and µ
∗
X2
. Using that Uα1N,j(α1,µX2)
is continuously differentiable in (αT1 ,µ
T
X2
)T and Θ is compact:
(27)
∂2
∂α⊗21
Uα1N,j(α˜1,µ
∗
X2) = Op(1),
∂2
∂µ⊗2X2
Uα1N,j(α̂1, µ˜X2) = Op(1),
∂2
∂α1∂µX2
Uα1N,j(
˜˜α1,µ∗X2) = Op(1).
Moreover, we have:
(28)
∂
∂α
T
1
Uα1N,j(α
∗
1,µ
∗
X2) = E
[
exp{α∗T1 (X− µ∗X2)}(Xj − µ∗X2,j)(X− µ∗X2)TI(T = 1)
]
+ op(1)
= −Jα1j (α∗1,µ∗X2) + op(1)
∂
∂µTX2
Uα1N,j(α
∗
1,µ
∗
X2) = −E
[
exp{α∗T1 (X− µ∗X2)}I(T = 1)1Tj
]
+ op(1),
where Xj and µX2,j denote the j-th element of X and µX2 and 1j denotes
a p× 1 vector that is 1 in the j-th position and 0 in the other positions. We
also used that α∗1 is the solution to Uα1(α1,µ∗X2) = 0.
Now for each j = 1, . . . , p, since Uα1N,j(α̂1, µ̂X2) = 0, re-arranging from
above yields:
(29)
{
−Jα1j (α∗1,µ∗X2) + op(1)
}
N1/2(α̂1 −α∗1) = −N1/2Uα1N,j(α∗1,µ∗X2)
− ∂
∂µTX2
Uα1N,j(α
∗
1,µ
∗
X2)N
1/2(µ̂X2 − µ∗X2) + op(1),
where we use that µ̂X2 is N
1/2-consistent. Considering the p components
simultaneously yields:
(30){−Jα1(α∗1,µ∗X2) + op(1)}N1/2(α̂1 −α∗1) = −N1/2Uα1N (α∗1,µ∗X2)
+ E
[
exp{α∗T1 (X− µ∗X2)}I(T = 1)1Tp×p
]
N1/2(µ̂X2 − µ∗X2) + op(1).
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Since µ̂X2 =
{∑N
i=1XiI(Ti = 2)
}
/
{∑N
i=1 I(Ti = 2)
}
, its influence function
is given by:
(31) N1/2(µ̂X2 − µ∗X2) = N−1/2
N∑
i=1
(Xi − µ∗X2)
I(Ti = 2)
P (Ti = 2)
+ op(1).
Finally, since Jα1(α∗1,µ∗X2) is non-singular:
(32)
N1/2(α̂1 −α∗1) = Jα1(α∗1,µ∗X2)−1
(
N1/2Uα1N (α
∗
1,µ
∗
X2)
− E
[
exp{α∗T1 (X− µ∗X2)}I(T = 1)
]
N−1/2
N∑
i=1
(Xi − µ∗X2)
I(Ti = 2)
P (Ti = 2)
)
+ op(1)
= N−1/2
N∑
i=1
Jα1(α∗1,µ
∗
X2)
−1 {Uα1i (α∗1,µ∗X2) +UµX2i (α∗1,µ∗X2)}+ op(1)
= N−1/2
N∑
i=1
ϕα1i (α
∗
1,µ
∗
X2) + op(1).
C.2. Proof of Theorem 2.2. Let the estimating equation associated
with ∆̂ be:
(33) U∆N (∆, µ1) = N
−1
N∑
i=1
(µ1 − Yi −∆)I(Ti = 2, Zi = 2).
We will directly identify the influence function expansion for ∆̂, which
implies that ∆̂
p→ ∆∗, when the identification assumptions hold and the
trial assignment is correctly specified. First we decompose U∆N (∆̂, µ̂1):
(34)
U∆N (∆̂, µ̂1) = U
∆
N (∆
∗, µ∗1) + U
∆
N (∆̂, µ
∗
1)− U∆N (∆∗, µ∗1) + U∆N (∆̂, µ̂1)− U∆N (∆̂, µ∗1)
= U∆N (∆
∗, µ∗1) +N
−1
N∑
i=1
−I(Ti = 2, Zi = 2)(∆̂−∆∗)
+N−1
N∑
i=1
I(Ti = 2, Zi = 2)(µ̂1 − µ∗1).
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Since U∆N (∆̂, µ̂1) = 0, re-arranging from above:
(35)
N1/2(∆̂−∆∗) = N1/2
{
U∆N (∆
∗, µ∗1) +N
−1
N∑
i=1
I(Ti = 2, Zi = 2)(µ̂1 − µ∗1)
}
/{
N−1
N∑
i=1
I(Ti = 2, Zi = 2)
}
= N−1/2
N∑
i=1
(µ∗1 − Yi −∆∗)
I(Zi = 2, Ti = 2)
P (Zi = 2, Ti = 2)
+N1/2(µ̂1 − µ1) + op(1).
Now let the estimating equation for µ̂1 be denoted:
(36) Uµ1N (µ1,α1) = N
−1
N∑
i=1
(Yi − µ1)exp(αT1Xi)I(Ti = 1, Zi = 1).
We can decompose Uµ1N (µ̂1, α̂1) as:
(37)
Uµ1N (µ̂1, α̂1) = U
µ1
N (µ
∗
1,α
∗
1) + U
µ1
N (µ̂1,α
∗
1)− Uµ1N (µ∗1,α∗1) + Uµ1N (µ̂1, α̂1)− Uµ1N (µ̂1,α∗1)
= Uµ1N (µ
∗
1,α
∗
1)−N−1
N∑
i=1
exp(α∗T1 Xi)I(Ti = 1, Zi = 1)(µ̂1 − µ∗1)
+
∂
∂α
T
1
Uµ1N (µ
∗
1,α
∗
1)(α̂1 −α∗1) +
∂2
∂α⊗21
Uµ1N (µ̂1, α˜1)(α̂1 −α∗1)⊗2
+
∂
∂µ1
∂
∂α
T
1
Uµ1N (µ˜1,α
∗
1)(α̂1 −α∗1)(µ̂1 − µ1),
where α˜1 and µ˜1 are such that ‖α˜1 −α∗1‖ ≤ ‖α̂1 −α∗1‖ and ‖µ˜1 − µ∗1‖ ≤
‖µ̂1 − µ∗1‖. Now using that Uµ1N (µ1,α1) is twice continuously differentaible
and Θ is compact, it can be shown that:
(38)
∂2
∂α⊗21
Uµ1N (µ̂1, α˜1) = Op(1) and
∂
∂µ1
∂
∂α
T
1
Uµ1N (µ˜1,α
∗
1) = Op(1).
Since Uµ1N (µ̂1, α̂1) = 0, re-arranging yields:
(39)
{
N−1
N∑
i=1
exp(α∗T1 Xi)I(Ti = 1, Zi = 1) + op(1)
}
N1/2(µ̂1 − µ∗1)
= N1/2
{
Uµ1N (µ
∗
1,α
∗
1) +
∂
∂α
T
1
Uµ1N (µ
∗
1,α
∗
1)(α̂1 −α∗1)
}
+ op(1).
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Now substituting the influence function expansion from Theorem 2.1
yields that:
(40)
N1/2(µ̂1 − µ∗1) = N−1/2
N∑
i=1
Jµ1(α∗1)
−1(Yi − µ∗1)exp(α∗T1 Xi)I(Ti = 1, Zi = 1)
+ Jµ1(α∗1)
−1C˜1(µ∗1,α
∗
1)
Tϕα1i (α
∗
1,µ
∗
X2) + op(1).
Returning to (39), we conclude that:
(41)
N1/2(∆̂−∆∗) = N−1/2
N∑
i=1
ϕµ2i (∆
∗, µ∗1) + ϕ
µ1
i (µ
∗
1,α
∗
1)
+ Jµ1(α∗1)
−1C˜1(µ∗1,α
∗
1)
Tϕα1i (α
∗
1,µ
∗
X2) + op(1)
= N−1/2
N∑
i=1
ϕi(∆
∗, µ∗1,α
∗
1,µ
∗
X2) + op(1).
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C.3. Proof of Lemma 2.1. From direct calculation:
(42)
V ar{ϕ˜α1i (α1, µ1,µX2)} = Jµ1(α1)−2C˜1(µ1,α1)Jα1(α1,µX2)−1
V ar
{
Uα1i (α1,µX2)
}
Jα1(α1,µX2)
−1C˜1(µ1,α1)
= Jµ1(α1)
−2C˜1(µ1,α1)TJα1(α1,µX2)
−1
E{(Xi − µX2)(Xi − µX2)Te2α
T
1 (Xi−µX2 )I(Ti = 1)}Jα1(α1,µX2)−1C˜1(µ1,α1)
Cov{ϕµ1i (µ1,α1), ϕ˜α1i (α1, µ1,µX2)} = Jµ1(α1)−2C˜1(µ1,α1)TJα1(α1,µX2)−1
E{Uα1i (α1,µX2)(Yi − µ1)eα
T
1XiI(Zi = 1, Ti = 1)}
= Jµ1(α1)
−2C˜1(µ1,α1)TJα1(α1,µX2)
−1eα
T
1µX2
E{(Xi − µX2)(Yi − µ1)e2α
T
1 (Xi−µX2 )I(Zi = 1, Ti = 1)}
V ar{ϕ˜µX2i (µX2 , µ1,α1)} = Jµ1(α1)−2C˜1(µ1,α1)Jα1(α1,µX2)−1
V ar
{
U
µX2
i (α1,µX2)
}
Jα1(α1,µX2)
−1C˜1(µ1,α1)
=
E
[
eα
T
1 (Xi−µX2 )I(Ti = 1)
]2
Jµ1(α1)2P (Ti = 2)
C˜1(µ1,α1)
TJα1(α1,µX2)
−1
V ar(Xi|Ti = 2)Jα1(α1,µX2)−1C˜1(µ1,α1)
Cov{ϕµ2(∆, µ1), ϕ˜µX2i (α1, µ1,µX2)} =
E
[
eα
T
1 (Xi−µX2 )I(Ti = 1)
]
Jµ1(α1)P (Ti = 2)
C˜1(µ1,α1)
TJα1(α1,µX2)
−1C˜2.
In the case where (2.1), (2.2), (2.4), and (2.3) hold and (5) is correctly
specified, note that:
(43)
C˜1(µ1,α1) = E
{
Xi(Yi − µ1)ω(Xi)e−α0I(Zi = 1, Ti = 1)
}
= E {Xi(Yi(1)− µ1)P (Ti = 2|Xi)} e−α0P (Zi = 1|Ti = 1)
= C1e
−α0P (Zi = 1|Ti = 1)P (Ti = 2)
Jα1(α1,µX2) = −E
[
(Xi − µX2)(Xi − µX2)Tω(Xi)e−α0−α
T
1µX2 I(Ti = 1)
]
= −E
[
(Xi − µX2)(Xi − µX2)TP (Ti = 2|Xi)
]
e−α0−α
T
1µX2
= −V ar(Xi|Ti = 2)P (Ti = 2)e−α0−α
T
1µX2 ,
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and:
(44)
E
[
eα
T
1 (Xi−µX2 )I(Ti = 1)
]
= E
[
ω(Xi)e
−α0−αT1µX2 I(Ti = 1)
]
= P (Ti = 2)e
−α0−αT1µX2
Jµ1(α1) = E{ω(Xi)I(Zi = 1, Ti = 1)}e−α0
= P (Ti = 2)P (Zi = 1|Ti = 1)e−α0 .
Consequently under these assumptions after evaluating parameters at the
truth and simplification:
(45)
V ar(ϕ˜α1i ) = P (Ti = 2)
−1CT1 V ar(Xi|Ti = 2)−1
E{(Xi − µ∗X2)(Xi − µ∗X2)Tω(Xi)|Ti = 2}V ar(Xi|Ti = 2)−1C1
Cov(ϕµ1i , ϕ˜
α1
i ) = −P (Ti = 2)−1C1V ar(Xi|Ti = 2)−1
E{(Xi − µ∗X2)(Yi(1)− µ∗1)ω(Xi)|Ti = 2}
V ar(ϕ˜
µX2
i ) = P (Ti = 2)
−1CT1 V ar(Xi|Ti = 2)−1C1
Cov(ϕµ2i , ϕ˜
µX2
i ) = −P (Ti = 2)−1CT1 V ar(Xi|Ti = 2)−1C2.
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